Scientists from the Oxford Vaccine Group (OVG) are rapidly developing a vaccine for the Bundibugyo strain of Ebola, which is currently causing a significant outbreak in the Democratic Republic of the Congo (DRC). The outbreak has led to 750 suspected cases and 177 deaths, prompting the World Health Organization (WHO) to raise the risk level from 'high' to 'very high.' The OVG is leveraging the same technology used in its Covid-19 vaccine to create this new vaccine, which is designed to instruct the immune system to recognize and combat the Bundibugyo virus without causing infection. Although the vaccine is still in development, it could enter clinical trials in as little as two to three months. The WHO has emphasized the urgency of the situation, declaring a public health emergency of international concern. In preparation for potential mass production, the Serum Institute of India is ready to manufacture the vaccine as soon as Oxford supplies the necessary medical-grade materials. Vaccination efforts will be targeted at healthcare workers and individuals at high risk of exposure rather than the general population.